Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease

NCT02556021 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-erosive Reflux Disease

Interventions

DRUG: CJ-12420 50mg
DRUG: CJ-12420 100mg
DRUG: Placebo

Sponsor

HK inno.N Corporation